AADI vs. NMRA, URGN, KRRO, ALMS, VYGR, LFCR, LFVN, AMRN, ZYBT, and SLDB
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Neumora Therapeutics (NMRA), UroGen Pharma (URGN), Korro Bio (KRRO), Alumis (ALMS), Voyager Therapeutics (VYGR), Lifecore Biomedical (LFCR), LifeVantage (LFVN), Amarin (AMRN), Zhengye Biotechnology (ZYBT), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs.
Aadi Bioscience (NASDAQ:AADI) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Neumora Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Neumora Therapeutics' return on equity.
Neumora Therapeutics received 17 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 77.78% of users gave Neumora Therapeutics an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 26.4% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Aadi Bioscience has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Aadi Bioscience currently has a consensus price target of $1.67, suggesting a potential downside of 13.64%. Neumora Therapeutics has a consensus price target of $10.14, suggesting a potential upside of 624.49%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Aadi Bioscience.
In the previous week, Neumora Therapeutics had 47 more articles in the media than Aadi Bioscience. MarketBeat recorded 48 mentions for Neumora Therapeutics and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 1.87 beat Neumora Therapeutics' score of 0.10 indicating that Aadi Bioscience is being referred to more favorably in the media.
Summary
Neumora Therapeutics beats Aadi Bioscience on 10 of the 17 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 3/14/2025 by MarketBeat.com Staff
